Journal
BIOMATERIALS
Volume 31, Issue 14, Pages 4179-4185Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2010.01.142
Keywords
Alzheimer's disease; Amyloid-beta; Curcumin; Keto-enol tautomerism; Amyloid detection
Funding
- JST
Ask authors/readers for more resources
Curcumin, which can exist in an equilibrium between keto and enol tautomers, binds to beta-amyloid (A beta) fibrils/aggregates. The aim of this study was to assess the relationship between the tautomeric structures of curcumin derivatives and their A beta-binding activities. Curcumin derivatives with keto-enol tautomerism showed high levels of binding to A beta aggregates but not to All monomers. The binding activity of the keto form analogue of curcumin to All aggregates was found to be much weaker than that of curcumin derivatives with keto-enol tautomerism. The color of a curcumin derivative with keto-enol tautomerism, which was substituted at the C-4 position, changed from yellow to orange within 30 min of being combined with All aggregates in physiological buffer. This resulted from a remarkable increase in the enol form with extended conjugation of double bonds upon binding. These findings suggest that curcumin derivatives exist predominantly in the enol form during binding to A beta aggregates, and that the enolization of curcumin derivatives is crucial for binding to A beta aggregates. The keto-enol tautomerism of curcumin derivatives may be a novel target for the design of amyloid-binding agents that can be used both for therapy and for amyloid detection in Alzheimer's disease. (C) 2010 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available